

(10-2003)
10 CFR 2.201

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Tawas St. Joseph Hospital
P.O. Box 659 / 200 Hemlock
Tawas City, MI 48764-0659

2. NRC/REGIONAL OFFICE

UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, IL 60532-4352

REPORT 2006-001

3. DOCKET NUMBER(S)

030-17606

4. LICENSEE NUMBER(S)

21-18979-01

5. DATE(S) OF INSPECTION

January 19, 2006

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

- ☒ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.


_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

- ☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		1/19/06

Docket File Information
**SAFETY INSPECTION REPORT
AND COMPLIANCE INSPECTION**

1. LICENSEE Tawas St. Joseph Hospital REPORT NUMBER(S) 2005-001		2. NRC/REGIONAL OFFICE Region III					
3. DOCKET NUMBER(S) 03017606		4. LICENSE NUMBER(S) 21-18979-01		5. DATE(S) OF INSPECTION January 19, 2006			
6. INSPECTION PROCEDURES USED 87131		7. INSPECTION FOCUS AREAS 03.01 - 03.07					
SUPPLEMENTAL INSPECTION INFORMATION							
1. PROGRAM CODE(S) 02120		2. PRIORITY 3		3. LICENSEE CONTACT Rick Phillips, NMT		4. TELEPHONE NUMBER 989/362-3411	
<input checked="" type="checkbox"/> Main Office Inspection		Next Inspection Date: January 2009					
<input type="checkbox"/> Field							
<input type="checkbox"/> Temporary Job Site							

PROGRAM SCOPE

The licensee was a medical facility located in Tawas City, Michigan, with authorization by the license to use any byproduct material permitted by 10 CFR 35.100, 35.200, 35.300, as needed limited to use as out-patient therapeutic treatments. Three nuclear medicine technologists (NMT) routinely perform an average of 12 procedures/administrations per day for routine cardiac tests (avg. 6 patients per day), bone scans, or other studies/scans as ordered. Xe-133 is used one to two times per week. No I-131 dosages greater than 30 millicuries are administered and other I-131 dosages less than 30 millicuries average 4 procedures per year. Tc-99m dosages are prepared from a 4.5 curie generator received each week. Other licensed material is ordered from a Traverse City, MI, nuclear pharmacy.

Performance Observations

During the inspection, the licensee's NMTs demonstrated/discussed: (1) survey meter use and calibration; (2) Generator procedures; (3) package check-in and return procedures; (4) dose prep, safe use, and labeling; (5) package wipe test counting; (6) dosimetry; (7) dose calibrator tests; (8) waste handling; (9) security of licensed materials; (10) sealed source inventory; (11) radiation safety program audits; and (12) iodine-131 procedures and written directives.